Information Provided By: 
Fly News Breaks for November 4, 2015
PETX
Nov 4, 2015 | 07:01 EDT
Piper Jaffray analyst Kevin Ellich views the recent pullback in shares of Aratana Therapeutics as overdone. The company's lymphoma products, AT-004 and AT-005, are some of its smaller opportunities and more attention should be put on Aratana's lead products for pain, inappetence, and post-op surgery pain, Ellich tells investors in a research note. He cut his price target for shares to $15 from $25 and maintains an Overweight rating on the name.
News For PETX From the Last 2 Days
There are no results for your query PETX
